Champiat S, et al. (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23:1920–1928.
 Kamada T, Togashi Y, Tay C, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J]. Proceedings of the National Academy of Sciences, 2019: 201822001.
 Zhang B, Chikuma S, Hori S, Fagarasan S, Honjo T (2016) Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci USA 113:8490–8495.
 Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4.
 Zhang R, et al. (2013) An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest 123:580–593.
 Levine AG, Arvey A, Jin W, Rudensky AY (2014) Continuous requirement for the TCR in regulatory T cell function. Nat Immunol 15:1070–1078.
 Ha D, et al. (2019) Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci USA 116:609–618.
 Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1270–1271.
 Hamid O, et al. (2016) First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.J Clin Oncol 34(Suppl 15):3079.
 Yamamoto N, et al. (2017) Anti-CC-chemokine receptor 4 (CCR4) antibody mogamulizumab (Moga) and nivolumab (Nivo) combination phase I study in patents with advanced or metastatic solid tumor. Ann Oncol 28(Suppl 5):v605–v649.
 hu J, et al. (2018) IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight 3:e98745.
本文作者 | 代丝雨